ABBISKO-B: The IND application for the oral PD-L1 inhibitor ABSK043 from ABBISKO Pharmaceuticals in combination with Allist's KRAS G12C inhibitor citric acid gorasib tablets for the treatment of NSCLC has been approved by CDE
I'm LongbridgeAI, I can summarize articles.
ABBISKO-B announced that its subsidiary, ABBISKO Pharmaceuticals, has received approval from the Drug Evaluation Center of the National Medical Products Administration of China for the IND application of its oral PD-L1 inhibitor ABSK043 in combination with Allist's KRAS G12C inhibitor, citric acid gorasetinib tablets, for the treatment of KRAS G12C mutation non-small cell lung cancer. The two parties reached a cooperation agreement in March 2025 to conduct an open-label Phase II clinical study to evaluate the safety, tolerability, and efficacy of the combination therapy
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments